Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lincomycin Hydrochloride

FDA-approved product (capsule, oral), marketed as Lincocin, Lincomycin Hydrochloride.

Registered studies
50+
Lab records
9
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lincomycin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Multiple sclerosis
  • Pseudomembranous enterocolitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FF02

Repurposing investigation

Lincomycin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae8.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis4.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 3 lab records
  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 1 lab record
  • M. tuberculosis: measured active in 0 of 4 lab records
Open Lincomycin Hydrochloride in ChEMBL Registered studies below
Show the 9 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lincomycin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis

    NCT06841003 · start 2025-02

    Registered record
    Registry ID
    NCT06841003
    Conditions
    Complicated Appendicitis; Intra-Abdominal Abscess
    Interventions
    Laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-02
    Completion
    2027-05
    Enrolment
    752

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Appendicitis; Intra-Abdominal Abscess
    InterventionLaparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin
    PhasePhase 3
    Registry statusNot yet recruiting

  • Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery

    NCT06207786 · start 2024-09-01

    Registered record
    Registry ID
    NCT06207786
    Conditions
    Skin Cancer; Skin Cancer Face; Malignant Cutaneous Adnexal Neoplasm
    Interventions
    Povidone-Iodine Swabs; Staphylococcus nasal swab; Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2024-09-01
    Completion
    2030-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Cancer; Skin Cancer Face; Malignant Cutaneous Adnexal Neoplasm
    InterventionPovidone-Iodine Swabs; Staphylococcus nasal swab; Antibiotic
    PhaseNot applicable
    Registry statusWithdrawn

  • Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

    NCT06494072 · start 2024-08-22

    Registered record
    Registry ID
    NCT06494072
    Conditions
    Community Acquired Pneumonia in Children
    Interventions
    Ampicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection; Amoxicillin-clavulanate; Clindamycin; Cefprozil; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-22
    Completion
    2028-05
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia in Children
    InterventionAmpicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection +4 more
    PhasePhase 4
    Registry statusRecruiting

  • An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

    NCT06422221 · start 2024-07-15

    Registered record
    Registry ID
    NCT06422221
    Conditions
    Bacteremia; Endocarditis
    Interventions
    Clindamycin; Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-07-15
    Completion
    2025-06-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia; Endocarditis
    InterventionClindamycin; Doxycycline
    PhasePhase 4
    Registry statusUnknown

  • Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia

    NCT06336824 · start 2024-06-28

    Registered record
    Registry ID
    NCT06336824
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2024-06-28
    Completion
    2025-06
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionTab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid; IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
    PhasePhase 3
    Registry statusUnknown

  • CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

    NCT05846399 · start 2023-09-07

    Registered record
    Registry ID
    NCT05846399
    Conditions
    Cat Bite; Hand Injuries; Arm Injury; Infection, Bacterial; Anti-bacterial Agents
    Interventions
    Amoxicillin/clavulanate; Ciprofloxacin; Clindamycin; Placebo (microcrystalline cellulose); Wound management
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-09-07
    Completion
    2027-08-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCat Bite; Hand Injuries; Arm Injury; Infection, Bacterial +1 more
    InterventionAmoxicillin/clavulanate; Ciprofloxacin; Clindamycin; Placebo (microcrystalline cellulose) +1 more
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy of Laser Hair Removal Therapy in HS

    NCT05762484 · start 2023-04

    Registered record
    Registry ID
    NCT05762484
    Conditions
    Hidradenitis Suppurativa, Acne Inversa
    Interventions
    Nd:YAG laser hair removal; Clindamycin 1 % Topical Lotion
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-04
    Completion
    2026-04
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHidradenitis Suppurativa, Acne Inversa
    InterventionNd:YAG laser hair removal; Clindamycin 1 % Topical Lotion
    PhaseNot applicable
    Registry statusUnknown

  • Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris

    NCT05926869 · start 2022-08-01

    Registered record
    Registry ID
    NCT05926869
    Conditions
    Acne Vulgaris
    Interventions
    Clindamycin and Dapsone gel for 03 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2023-02-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionClindamycin and Dapsone gel for 03 months
    PhasePhase 2
    Registry statusCompleted

  • Staphylococcus Aureus Network Adaptive Platform Trial

    NCT05137119 · start 2022-02-16

    Registered record
    Registry ID
    NCT05137119
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Cefazolin; Penicillin; Clindamycin; Vancomycin; Effectiveness of early switch to oral antibiotics; Whole body FDG PET/CT Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-16
    Completion
    2028-12-01
    Enrolment
    8,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionCefazolin; Penicillin; Clindamycin; Vancomycin +2 more
    PhasePhase 4
    Registry statusRecruiting

  • The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions

    NCT03357419 · start 2021-03

    Registered record
    Registry ID
    NCT03357419
    Conditions
    Skin Lesion
    Interventions
    Cephalexin; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2021-03
    Completion
    2022-03-27
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Lesion
    InterventionCephalexin; Placebo oral capsule
    PhaseNot applicable
    Registry statusWithdrawn

  • Antibiotic Prophylaxis in Rhinoplasty

    NCT04194216 · start 2020-05-20

    Registered record
    Registry ID
    NCT04194216
    Conditions
    Nasal Obstruction; Nasal Surgical Procedures
    Interventions
    Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.; Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Enrolling by invitation
    Start
    2020-05-20
    Completion
    2027-04-20
    Enrolment
    864

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal Obstruction; Nasal Surgical Procedures
    InterventionIntra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.; Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
    PhasePhase 3
    Registry statusEnrolling by invitation

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix

    NCT06541236 · start 2019-09-01

    Registered record
    Registry ID
    NCT06541236
    Conditions
    To Evaluate the Quality of the Newly Formed Cortical Tissue in the Area of the Condylar Condyle Using Different Bone Grafting Materials
    Interventions
    Alveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-09-01
    Completion
    2024-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTo Evaluate the Quality of the Newly Formed Cortical Tissue in the Area of the Condylar Condyle Using Different Bone Grafting Materials
    InterventionAlveolar Ridge Preservation After Tooth Extraction Using Autologous Dentin Matrix
    PhaseNot applicable
    Registry statusUnknown

  • Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

    NCT04134273 · start 2019-03-20

    Registered record
    Registry ID
    NCT04134273
    Conditions
    Acne Vulgaris
    Interventions
    CLPG Topical Gel 1%; Clindamycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-03-20
    Completion
    2019-10-15
    Enrolment
    1,260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionCLPG Topical Gel 1%; Clindamycin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

    NCT03723551 · start 2019-02-20

    Registered record
    Registry ID
    NCT03723551
    Conditions
    Bone or Joint Infection
    Interventions
    Afabicin; Cefazolin; Vancomycin; Linezolid; Clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-02-20
    Completion
    2025-04-23
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone or Joint Infection
    InterventionAfabicin; Cefazolin; Vancomycin; Linezolid +1 more
    PhasePhase 2
    Registry statusTerminated